Quartiles of cholesterol absorption marker/total cholesterol (mg/mg*103)
  Q1 Q2 Q3 Q4 P-value
  (<4.6) (4.6-5.6) (5.6-7.2) (≥7.3)  
Number of subjects 30 30 30 31  
Men (%) 20 (70.0) 25 (83.3) 25 (83.3) 18 (58.1) N.S.
Age (years) 60.4 ± 10.1 61.7 ± 11.8 61.0 ± 12.1 60.6 ± 12.0 N.S.
Duration of diabetes (years) 10.9 (7.9) 12.9 (10.1) 13.5 (9.2) 12.8 (9.5) N.S.
Body Mass Index (kg/m2) 25.2 ± 4.1 25.1 ± 5.7 25.6 ± 5.1 24.2 ± 4.7 N.S.
Waist circumference (cm) 90.7 ± 9.7 89.8 ± 10.4 89.3 ± 11.8 86.5 ± 11.1 N.S.
Systolic BP (mmHg) 135.1 ± 11.3 133.2 ± 12.5 130.3 ± 11.4 135.7 ± 13.3 N.S.
Diastolic BP (mmHg) 76.7 ± 10.5 74.3 ± 11.4 74.3 ± 9.2 74.8 ± 9.3 N.S.
Triglycerides (mg/dL) 157.1 ± 137.6 108.1 ± 64.1 170.1 ± 256.5 109.5 ± 67.7 N.S.
HDL cholesterol (mg/dL) 50.4 ± 10.4 55.7 ± 16.8 54.2 ± 13.6 62.4 ± 15.8 0.003
LDL cholesterol (mg/dL) 128.6 ± 31.3 131.5 ± 18.1 143.4 ± 27.3 145.0 ± 25.4 0.004
RLP cholesterol (mg/dL) 6.2 ± 7.0 4.5 ± 2.6 5.3 ± 2.4 5.2 ± 3.2 N.S.
Cholesterol synthesis marker/total cholesterol (mg/mg*103) 2.4 ± 1.7 2.1 ± 1.4 2.0 ± 1.3 1.6 ± 0.9 0.014
A1C (%) 7.5 ± 1.2 7.4 ± 1.1 7.4 ± 1.0 7.2 ± 0.9 N.S.
Fasting blood glucose (mg/dL) 144.0 ± 32.4 147.7 ± 58.0 135.5 ± 44.1 127.5 ± 32.0 N.S.
CPR (ng/mL) 2.0 ± 1.0 1.8 ± 1.1 1.7 ± 1.1 1.3 ± 0.8 0.009
hs-CRP (ng/mL) 1098.2 ± 1560.4 1506.4 ± 1936.4 971.8 ± 1140.0 877.4 ± 1799.3 N.S.
History of coronary artery disease (%) 1 (3.3) 2 (6.7) 1 (3.3) 1 (3.3) N.S.
History of stroke (%) 4 (13.3) 0 (0.0) 2 (6.7) 3 (10.0) N.S.
Hypertension (%) 12 (40.0) 10 (33.3) 8 (26.7) 12 (38.7) N.S.
Smoking (%) 7 (23.3) 4 (13.3) 4 (13.3) 8 (25.8) N.S.
CPR: C-peptide reactivity. CPR (reference value): 1.2 to 2.0 ng/mL, hs-CRP: high-sensitivity C-reactive protein
Table 2: Clinical data according to quartiles of cholesterol absorption markers in 121 type-2 diabetic patients without any lipid lowering therapy.